Characterization of the Fungal Immunopeptidome Involved in the Immunopathological Mechanisms of Psoriasis

NCT06610942 | Not Yet Recruiting

• 2 other identifiers: APHP2409682024-A01701-46
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Psoriasis is a chronic immune-mediated skin disorder characterized by inflammatory cutaneous plaques and, occasionally, arthritis, affecting 60 million adults and children worldwide. Although a variety of treatments have been developed aimed to relieve the associated symptoms, there is yet no permanent cure for psoriasis. TH17 type immunity, via the production of IL-17A and other pro-inflammatory cytokines, are considered to play a central role in the pathogenesis of this disease. Moreover, experimental evidence obtained in animal models, points to human mycobiota as a trigger for the initiation and/or progression of psoriasis. Therefore, human studies are required to better characterize the major fungi implicated in the local and systemic inflammatory responses, as well as to determine the immunopeptidome that shapes the pathogenic T cell receptor repertoire. We will explore the hypothesis that commensal fungi could participate in the chronic inflammatory immune response underlying the pathogenesis of human psoriasis via the recognition of cutaneous fungal antigens and/or via a gut-skin mycobiome cross-reactive mechanism

Conditions

Psoriasis

Keywords

Fungi; immunopeptidome; psoriasis; IL17

Outcome Measures

Primary Outcomes (1)

• Determining the commensal fungi responsible for the immunopathological response in psoriasis.

  Flow cytometry analysis of cytokine secretion profile in healthy and diseased subjects

  2 years

Secondary Outcomes (1)

• Identification of peptides responsible for the immunopathological response in psoriasis.

  2 years

Study Arms (3)

Adult patients with psoriasis who have failed local treatment

"Healthy" controls (skin)

"Healthy" controls (stools)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with psoriasis failing local treatment. Studying various biological samples from these patients (skin, blood, stools, and skin swabs) will allow the investigation of the local and systemic immune response and an attempt to understand the involvement of the skin and intestinal mycobiome. Healthy controls (skin): Adult patients undergoing reconstructive surgery where healthy skin is removed. Studying samples of healthy skin will enable the investigation of the skin immune response in subjects without skin disease or autoimmune disease. Healt controls (stools): Living in the same household as the patient with psoriasis. This population will allow the study of the intestinal mycobiome in controls with environments and diets similar to those of patients with psoriasis. Healthy controls (blood): Blood samples from donors obtained from the French Blood Establishment (EFS). These samples will allow the study of the systemic immune response to better understand the

You may qualify if:

• Adults with psoriasis failing local treatment. Adults requiring reconstructive plastic surgery (resident skin immunology checks).
• Adults living in the same household as a patient suffering from psoriasis (intestinal mycobiome checks).

You may not qualify if:

• Minors Individuals under legal protection. Pregnant or breastfeeding women

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Service de Parasitologie-Mycologie Hôpital St Antoine

Paris, 75012, France

Location

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Alicia MORENO, Doctor

CONTACT

+33 149282000; alicia.moreno@aphp.fr

Alicia MORENO

CONTACT

alicia.moreno@aphp.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 20, 2024
• First Posted: September 24, 2024
• Study Start: October 1, 2025
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2027
• Last Updated: August 26, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)